Tazobactam/piperacillin for moderate-to-severe pneumonia in patients with risk for aspiration: Comparison with imipenem/cilastatin

Pulmonary Pharmacology and Therapeutics

Volumn 23, Issue 5, 2010, Pages 403-410

  Ito, Isao ^a,b   Kadowaki, Seizo ^b   Tanabe, Naoya ^a   Haruna, Akane ^a   Kase, Masahito ^b   Yasutomo, Yoshiro ^b   Tsukino, Mitsuhiro ^c   Nakai, Asako ^a   Matsumoto, Hisako ^a   Niimi, Akio ^a   Chin, Kazuo ^a   Ichiyama, Satoshi ^a   Mishima, Michiaki ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b Ono Municipal Hospital   (Japan)

^c Hikone Municipal Hospital   (Japan)

Author keywords

Aspiration; Community acquired pneumonia (CAP); Imipenem cilastain (IPM CS); Nursing home acquired pneumonia (NHAP); Open label randomized study; Tazobactam piperacillin (TAZ PIPC)

Indexed keywords

C REACTIVE PROTEIN; CILASTATIN PLUS IMIPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ABNORMAL FECES COMPOSITION; ACUTE KIDNEY FAILURE; AGED; ARTICLE; ASPIRATION PNEUMONIA; AXILLA TEMPERATURE; BACTERIAL PNEUMONIA; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; FEMALE; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; NURSING HOME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SIDE EFFECT; TARRY FECES; THROMBOCYTOPENIA; TREATMENT OUTCOME;

AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CILASTATIN; COMMUNITY-ACQUIRED INFECTIONS; DRUG COMBINATIONS; FEMALE; HUMANS; IMIPENEM; INJECTIONS, INTRAVENOUS; MALE; NURSING HOMES; PENICILLANIC ACID; PIPERACILLIN; PNEUMONIA, ASPIRATION; PROSPECTIVE STUDIES; PROTEASE INHIBITORS; TREATMENT OUTCOME;

EID: 77955467849     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2010.05.007     Document Type: Article

References (41)

1. United Nations Population Division World population prospects: the 2006 revision 2007, United Nations Population Division, New York.
2. World Health Organization The World health report 2004 2004, World Health Organization, Geneva.
3. Ministry of Health Labour and Welfare, Government of Japan Summary of vital statistics 2006 (in Japanese) 2007, Ministry of Health Labour and Welfare, Government of Japan, Tokyo.
4. Kikuchi R., Watabe N., Konno T., Mishina N., Sekizawa K., Sasaki H. High incidence of silent aspiration in elderly patients with community-acquired pneumonia. Am J Respir Crit Care Med 1994, 150:251-253.
5. Hammond J.M., Potgieter P.D., Hanslo D., Scott H., Roditi D. The etiology and antimicrobial susceptibility patterns of microorganisms in acute community-acquired lung abscess. Chest 1995, 108:937-941.
6. Wang J.L., Chen K.Y., Fang C.T., Hsueh P.R., Yang P.C., Chang S.C. Changing bacteriology of adult community-acquired lung abscess in Taiwan: Klebsiella pneumoniae versus anaerobes. Clin Infect Dis 2005, 40:915-922.
7. Bartlett J.G., Gorbach S.L., Finegold S.M. The bacteriology of aspiration pneumonia. Am J Med 1974, 56:202-207.
8. El-Solh A.A., Pietrantoni C., Bhat A., Aquilina A.T., Okada M., Grover V., et al. Microbiology of severe aspiration pneumonia in institutionalized elderly. Am J Respir Crit Care Med 2003, 167:1650-1654.
9. Sanguinetti C.M., De Benedettob F., Miragliotta G. DEDALO Study Group. Bacterial agents of lower respiratory tract infections (LRTIs), β-lactamase production, and resistance to antibiotics in elderly people. Int J Antimicrob Agents 2000, 16:467-471.
10. Templeton K.E., Scheltinga S.A., van den Eeden W.C., Graffelman A.W., van den Broek P.J., Claas E.C. Improved diagnosis of the etiology of community-acquired pneumonia with real-time polymerase chain reaction. Clin Infect Dis 2005, 41:345-351.
11. Kadowaki M., Demura Y., Mizuno S., Uesaka D., Ameshima S., Miyamori I., et al. Reappraisal of clindamycin IV monotherapy for treatment of mild-to-moderate aspiration pneumonia in elderly patients. Chest 2005, 127:1276-1282.
12. Tokuyasu H., Harada T., Watanabe E., Okazaki R., Touge H., Kawasaki Y., et al. Effectiveness of meropenem for the treatment of aspiration pneumonia in elderly patients. Intern Med 2009, 48:129-135.
13. Yanagihara K., Fukuda Y., Seki M., Izumikawa K., Higashiyama Y., Miyazaki Y., et al. Clinical comparative study of sulbactam/ampicillin and imipenem/cilastatin in elderly patients with community-acquired pneumonia. Intern Med 2006, 45:995-999.
14. Carmeli Y., Troillet N., Eliopoulos G.M., Samore M.H. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999, 43:1379-1382.
15. Lepper P.M., Grusa E., Reichl H., Högel J., Trautmann M. Consumption of imipenem correlates with ß-lactam resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2002, 46:2920-2925.
16. Mandell L.A., Wunderink R.G., Anzueto A., Bartlett J.G., Campbell G.D., Dean N.C., et al. Infectious diseases society of America/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44:S27-S72.
17. Fine M.J., Auble T.E., Yealy D.M., Hanusa B.H., Weissfeld L.A., Singer D.E., et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997, 336:243-250.
18. British Thoracic Society Pneumonia Guidelines Committee. BTS guidelines for the management of community acquired pneumonia in adults-2004 update.
19. Ott S.R., Allewelt M., Lorenz J., Reimnitz P., Lode H. German Lung Abscess Study Group. Moxifloxacin vs ampicillin/sulbactam in aspiration pneumonia and primary lung abscess. Infection 2008, 36:23-30.
20. Allewelt M., Schüler P., Bölcskei P.L., Mauch H., Lode H. Study Group on Aspiration Pneumonia. Ampicillin + sulbactam vs. clindamycin ± cephalosporin for the treatment of aspiration pneumonia and primary lung abscess. Clin Microbiol Infect 2004, 10:163-170.
21. Marik P.E. Aspiration pneumonitis and aspiration pneumonia. N Engl J Med 2001, 344:665-671.
22. Ito I., Ishida T., Togashi K., Niimi A., Koyama H., Ishimori T., et al. Differentiation of bacterial and non-bacterial community-acquired pneumonia by thin-section computed tomography. Eur J Radiol 2009, 72:388-395.
23. Hoellman D.B., Kelly L.M., Credito K., Anthony L., Ednie L.M., Jacobs M.R., et al. In vitro antianaerobic activity of ertapenem (MK-0826) compared to seven other compounds. Antimicrob Agents Chemother 2002, 46:220-224.
24. Edmiston C.E., Krepel C.J., Kehl K.S., Seabrook G.R., Somberg L.B., Almassi G.H., et al. Comparative in vitro antimicrobial activity of a novel quinolone, garenoxacin, against aerobic and anaerobic microbial isolates recovered from general, vascular, cardiothoracic and otolaryngologic surgical patients. J Antimicrob Chemother 2005, 56:872-878.
25. Cometta A., Zinner S., de Bock R., Calandra T., Gaya H., Klastersky J., et al. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother 1995, 39:445-452.
26. Maruyama T., Niederman M.S., Kobayashi T., Kobayashi H., Takagi T., D'Alessandro-Gabazza C.N., et al. A prospective comparison of nursing home-acquired pneumonia with hospital-acquired pneumonia in non-intubated elderly. Respir Med 2008, 102:1287-1295.
27. Shindo Y., Sato S., Maruyama E., Ohashi T., Ogawa M., Hashimoto N., et al. Health-care-associated pneumonia among hospitalized patients in a Japanese community hospital. Chest 2009, 135:633-640.
28. Micek S.T., Kollef K.E., Reichley R.M., Roubinian N., Kollef M.H. Health care-associated pneumonia and community-acquired pneumonia: a single-center experience. Antimicrob Agents Chemother 2007, 51:3568-3573.
29. Kollef M.H., Shorr A., Tabak Y.P., Gupta V., Liu L.Z., Johannes R.S. Epidemiology and outcomes of health-care-associated pneumonia. Results from a large US database of culture-positive pneumonia. Chest 2005, 128:3854-3862.
30. American Thoracic Society; Infectious Diseases Society of America Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005, 171:388-416.
31. Jaccard C., Troillet N., Harbarth S., Zanetti G., Aymon D., Schneider R., et al. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother 1998, 42:2966-2972.
32. Joshi M., Metzler M., McCarthy M., Olvey S., Kassira W., Cooper A. Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia. Respir Med 2006, 100:1554-1565.
33. Schmitt D.V., Leitner E., Welte T., Lode H. Piperacillin/tazobactam vs imipenem/vilastatin in the treatment of nosocomial pneumonia-a double blind prospective multicentre study. Infection 2006, 34:127-134.
34. Joshi M., Bernstein J., Solomkin J., Wester B.A., Kuye O. Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin for the treatment of patients with nosocomial lower respiratory tract infection. J Antimicrob Chemother 1999, 43:389-397.
35. Brun-Buisson C., Sollet J.P., Schweich H., Brière S., Petit C. Treatment of ventilator-associated pneumonia with piperacillin-tazobactam/amikacin versus ceftazidime/amikacin: a multicenter, randomized controlled trial. Clin Infect Dis 1998, 26:346-354.
36. Matsumoto K., Nagatake T., Oishi K., Amamoto T., Urae R., Niki Y., et al. Evaluation of emergence of beta-lactam resistance in Pseudomonas aeruginosa (in Japanese). Chemotherapy 1994, 42(S2):281-299.
37. Mikamo H., Yamagishi Y. Strategic use of antimicrobial agents based on pharmacokinetics-pharmacodynamics (PK-PD) theory (in Japanese). ICC & CCU 2008, 32:269-279.
38. Kim M.K., Capitano B., Mattoes H.M., Xuan D., Quintiliani R., Nightingale C.H., et al. Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens for piperacillin-tazobactam. Pharmacotherapy 2002, 5:569-577.
39. Occhipinti D.J., Pendland S.L., Schoonover L.L., Rypins E.B., Danziger L.H., Rodvold K.A. Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens. Antimicrob Agents Chemother 1997, 41:2511-2517.
40. Frei C.R., Burgess D.S. Pharmacokinetic/pharmacodynamic modeling to predict in vivo effectiveness of various dosing regimens of piperacillin/tazobactam and piperacillin monotherapy against gram-negative pulmonary isolates from patients managed in intensive care units in 2002. Clin Ther 2008, 30:2335-2341.
41. Higashiya F., Mihashi S. Evaluation of antimicrobial effects and optimal ratio of tazobactam/piperacillin combination (in Japanese). Chemotherapy 1994, 42(S2):26-33.